Detection and Reporting of Organisms Producing Extended-Spectrum β-Lactamases: Survey of Laboratories in Connecticut
Open Access
- 1 December 1999
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 37 (12), 4065-4070
- https://doi.org/10.1128/jcm.37.12.4065-4070.1999
Abstract
Extended-spectrum β-lactamases (ESBLs) are enzymes produced in some gram-negative bacilli that mediate resistance to extended-spectrum cephalosporins and aztreonam. They are most common in Klebsiella spp. and Escherichia coli but are present in a variety of Enterobacteriaceae . Resistance mediated by these enzymes can be difficult to detect depending on the antimicrobial agents tested. AmpC β-lactamases are related to the chromosomal enzymes of Enterobacter and Citrobacter spp. and also mediate resistance to extended-spectrum cephalosporins and aztreonam in addition to cephamycins, such as cefoxitin. Unlike ESBLs, however, AmpC β-lactamases are not inhibited by clavulanic acid or other similar compounds. To assess the abilities of various antimicrobial susceptibility testing methods to detect ESBLs, we sent three ESBL-producing organisms, one AmpC-producing organism, and a control strain that was susceptible to extended-spectrum cephalosporins to 38 laboratories in Connecticut for testing. Eight (21.0%) of 38 labs failed to detect extended-spectrum cephalosporin or aztreonam resistance in any of the ESBL- or AmpC-producing isolates. Errors were encountered with both automated and disk diffusion methods. Conversely, seven (18.4%) labs categorized at least some of the four resistant isolates as potential ESBL producers and reported the results with the extended-spectrum cephalosporins and aztreonam as resistant as suggested by current National Committee for Clinical Laboratory Standards (NCCLS) guidelines. The percentage of laboratories that failed to detect resistance in the ESBL or AmpC isolates ranged from 23.7 to 31.6% depending on the type of enzyme present in the test organism. This survey suggests that many laboratories have difficulty detecting resistance in ESBL and AmpC-producing organisms and may be unaware of the NCCLS guidelines on modifying susceptibility testing reports for ESBL-producing strains.Keywords
This publication has 19 references indexed in Scilit:
- Bacterial and epidemiologic study of the resistance to oxyiminocephalosporins in Escherichia coli in a French hospitalClinical Microbiology & Infection, 1999
- Can Results Obtained with Commercially Available MicroScan Microdilution Panels Serve as an Indicator of β-Lactamase Production among Escherichia coli and Klebsiella Isolates with Hidden Resistance to ExpandedSpectrum Cephalosporins and Aztreonam?Journal of Clinical Microbiology, 1998
- Evolution and Dissemination of β-Lactamases Accelerated by Generations of β-Lactam AntibioticsClinical Infectious Diseases, 1997
- beta-Lactamases in laboratory and clinical resistanceClinical Microbiology Reviews, 1995
- A functional classification scheme for beta-lactamases and its correlation with molecular structureAntimicrobial Agents and Chemotherapy, 1995
- More extended-spectrum beta-lactamasesAntimicrobial Agents and Chemotherapy, 1991
- Outbreak of nosocomial infections due toKlebsiella pneumoniae producing SHV-4 beta-lactamaseEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- Effective cooling allows sonication to be used for liberation of β-lactamases from Gramnegative bacteriaJournal of Antimicrobial Chemotherapy, 1989
- Extended Broad-Spectrum -Lactamases Conferring Transferable Resistance to Newer -Lactam Agents in Enterobacteriaceae: Hospital Prevalence and Susceptibility PatternsClinical Infectious Diseases, 1988
- The Use of Analytical Isoelectric Focusing for Detection and Identification of -LactamasesJournal of General Microbiology, 1975